Account wins from the 04/10/07 news brief

Share this article:
Wunderman has been selected to launch a consumer campaign for AstraZeneca's Faslodex, a medication that has been approved for use in postmenopausal women with hormone-receptor positive metastatic breast cancer that has progressed following therapy with a hormonal treatment like tamoxifen. Wunderman will handle DTC and DTP relationship marketing efforts aimed at raising awareness in late stage breast cancer patients. A print campaign is slated for summer 2007. In addition to Faslodex, Wunderman currently handles Arimidex and Casodex/Zoladex. All are part of AstraZeneca's oncology catalog.
Share this article:
You must be a registered member of MMM to post a comment.
 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.